Next Article in Journal
A New Characterization of Mental Health Disorders Using Digital Behavioral Data: Evidence from Major Depressive Disorder
Next Article in Special Issue
Balloon Enteroscopy-Assisted Endoscopic Retrograde Cholangiopancreatography for the Treatment of Common Bile Duct Stones in Patients with Roux-en-Y Gastrectomy: Outcomes and Factors Affecting Complete Stone Extraction
Previous Article in Journal
Effectiveness of Mind–Body Intervention for Inflammatory Conditions: Results from a 26-Week Randomized, Non-Blinded, Parallel-Group Trial
Previous Article in Special Issue
Recent Advances of Interventional Endoscopic Retrograde Cholangiopancreatography and Endoscopic Ultrasound for Patients with Surgically Altered Anatomy
Review

Chemotherapy for Biliary Tract Cancer in 2021

Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan
*
Author to whom correspondence should be addressed.
Academic Editor: Stanley W. Ashley
J. Clin. Med. 2021, 10(14), 3108; https://doi.org/10.3390/jcm10143108
Received: 18 June 2021 / Revised: 12 July 2021 / Accepted: 13 July 2021 / Published: 14 July 2021
Biliary tract cancer refers to a group of malignancies including cholangiocarcinoma, gallbladder cancer, and ampullary cancer. While surgical resection is considered the only curative treatment, postoperative recurrence can sometimes occur. Adjuvant chemotherapy is used to prolong prognosis in some cases. Many unresectable cases are also treated with chemotherapy. Therefore, systemic chemotherapy is widely introduced for the treatment of biliary tract cancer. Evidence on chemotherapy for biliary tract cancer is recently on the increase. Combination chemotherapy with gemcitabine and cisplatin is currently the standard of care for first-line chemotherapy in advanced cases. Recently, FOLFOX also demonstrated efficacy as a second-line treatment. In addition, efficacies of isocitrate dehydrogenase inhibitors and fibroblast growth factor receptor inhibitors have been shown. In the adjuvant setting, capecitabine monotherapy has become the standard of care in Western countries. In addition to conventional cytotoxic agents, molecular-targeted agents and immunotherapy have been evaluated in multiple clinical trials. Genetic testing is used to check for genetic alterations and molecular-targeted agents and immunotherapy are introduced based on tumor characteristics. In this article, we review the latest evidence of chemotherapy for biliary tract cancer. View Full-Text
Keywords: biliary tract cancer; cholangiocarcinoma; chemotherapy; cytotoxic agents; molecular targeted agents; immunotherapy; precision medicine; genetic testing biliary tract cancer; cholangiocarcinoma; chemotherapy; cytotoxic agents; molecular targeted agents; immunotherapy; precision medicine; genetic testing
Show Figures

Figure 1

MDPI and ACS Style

Sasaki, T.; Takeda, T.; Okamoto, T.; Ozaka, M.; Sasahira, N. Chemotherapy for Biliary Tract Cancer in 2021. J. Clin. Med. 2021, 10, 3108. https://doi.org/10.3390/jcm10143108

AMA Style

Sasaki T, Takeda T, Okamoto T, Ozaka M, Sasahira N. Chemotherapy for Biliary Tract Cancer in 2021. Journal of Clinical Medicine. 2021; 10(14):3108. https://doi.org/10.3390/jcm10143108

Chicago/Turabian Style

Sasaki, Takashi, Tsuyoshi Takeda, Takeshi Okamoto, Masato Ozaka, and Naoki Sasahira. 2021. "Chemotherapy for Biliary Tract Cancer in 2021" Journal of Clinical Medicine 10, no. 14: 3108. https://doi.org/10.3390/jcm10143108

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop